Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07384429
PHASE4

Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease

Sponsor: YangPan

View on ClinicalTrials.gov

Summary

The aim of this study is to explore the effects of the dual orexin receptor antagonist Lemborexant on improving motor and sleep comorbidity in patients with Parkinson's disease. This study will provide clinical evidence for the application of dual orexin receptor antagonists in the treatment of Parkinson's Disease.

Official title: Study for the Dual Orexin Receptor Antagonist Lemborexant in Improving Motor-Sleep Comorbidity in Parkinson's Disease

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

44

Start Date

2026-03-19

Completion Date

2026-12-01

Last Updated

2026-03-23

Healthy Volunteers

No

Interventions

DRUG

Lemborexant

Participants will receive oral Lemborexant (5 mg/day) nightly approximately 5-30 minutes before going to bed for 28 consecutive days.

DRUG

placebo

Participants will receive a matching placebo nightly approximately 5-30 minutes before going to bed for 28 consecutive days.

Locations (1)

Zhongnan hospital

Wuhan, Hubei, China